Good Future and Chung Shan Medical University Hospital have published a breast-cancer circulating tumor cell study in MDPI Diseases.
The study used the Chiline CATCH automated negative selection platform and EpCAM plus CSV as the main identification markers.
The paper reported that CSV+ CTC counts, rather than EpCAM+ counts, were associated with higher metastatic risk.
CSV+ CTC counts also outperformed conventional serum tumor markers and were associated with worse progression-free survival at higher levels.
These findings highlight the value of an automated negative selection platform in preserving clinically meaningful CTC phenotypes.